{
 "drug": "Lopinavir and Ritonavir Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "07/24/2026",
 "dayN": 32,
 "cat": "Antiviral",
 "companies": [
  "AbbVie Inc."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "07/24/2026",
   "update_type": "New",
   "initial_posting_date": "07/24/2026",
   "package_ndc": "0074-0522-60",
   "generic_name": "Lopinavir and Ritonavir Tablet",
   "contact_info": "800-633-9110",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "07/24/2026",
   "therapeutic_category": [
    "Antiviral"
   ],
   "dosage_form": "Tablet",
   "presentation": "Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-0522-60)",
   "company_name": "AbbVie Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "07/24/2026",
   "update_type": "New",
   "initial_posting_date": "07/24/2026",
   "package_ndc": "0074-3008-60",
   "generic_name": "Lopinavir and Ritonavir Tablet",
   "contact_info": "800-633-9110",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA021906"
    ],
    "brand_name": [
     "KALETRA"
    ],
    "generic_name": [
     "LOPINAVIR AND RITONAVIR"
    ],
    "manufacturer_name": [
     "AbbVie Inc."
    ],
    "product_ndc": [
     "0074-3008",
     "0074-3956",
     "0074-4014"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "LOPINAVIR",
     "RITONAVIR"
    ],
    "rxcui": [
     "311369",
     "597730",
     "746645",
     "847741",
     "847745",
     "847749"
    ],
    "spl_id": [
     "36abdfba-ddc2-43ae-9173-903d66a23b23"
    ],
    "spl_set_id": [
     "8290add3-4449-4e58-6c97-8fe1eec972e3"
    ],
    "package_ndc": [
     "0074-3956-46",
     "0074-4014-12",
     "0074-3008-60"
    ],
    "nui": [
     "N0000000246",
     "N0000175889",
     "N0000185503",
     "N0000190114",
     "N0000190107",
     "N0000191001",
     "N0000182137",
     "N0000185607",
     "N0000190118",
     "N0000190113",
     "N0000182141",
     "N0000191266",
     "N0000185507",
     "N0000187064",
     "N0000190117"
    ],
    "pharm_class_moa": [
     "HIV Protease Inhibitors [MoA]",
     "P-Glycoprotein Inhibitors [MoA]",
     "Cytochrome P450 3A Inhibitors [MoA]",
     "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]",
     "Cytochrome P450 2D6 Inhibitors [MoA]",
     "Cytochrome P450 2C19 Inducers [MoA]",
     "Cytochrome P450 3A Inducers [MoA]",
     "Breast Cancer Resistance Protein Inhibitors [MoA]",
     "Cytochrome P450 3A4 Inhibitors [MoA]",
     "Cytochrome P450 1A2 Inducers [MoA]",
     "Cytochrome P450 2C9 Inducers [MoA]",
     "Cytochrome P450 2B6 Inducers [MoA]",
     "UDP Glucuronosyltransferases Inducers [MoA]"
    ],
    "pharm_class_epc": [
     "Protease Inhibitor [EPC]",
     "Cytochrome P450 3A Inhibitor [EPC]"
    ],
    "unii": [
     "2494G1JF75",
     "O3J8G9O825"
    ]
   },
   "update_date": "07/24/2026",
   "therapeutic_category": [
    "Antiviral"
   ],
   "dosage_form": "Tablet",
   "presentation": "Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60)",
   "company_name": "AbbVie Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "07/24/2026",
   "update_type": "New",
   "initial_posting_date": "07/24/2026",
   "package_ndc": "0074-6799-22",
   "generic_name": "Lopinavir and Ritonavir Tablet",
   "contact_info": "800-633-9110",
   "related_info": "Discontinuation of the manufacture of the drug",
   "update_date": "07/24/2026",
   "therapeutic_category": [
    "Antiviral"
   ],
   "dosage_form": "Tablet",
   "presentation": "Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-6799-22)",
   "company_name": "AbbVie Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "07/24/2026",
   "update_type": "New",
   "initial_posting_date": "07/24/2026",
   "package_ndc": "0074-4014-12",
   "generic_name": "Lopinavir and Ritonavir Tablet",
   "contact_info": "800-633-9110",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA021906"
    ],
    "brand_name": [
     "KALETRA"
    ],
    "generic_name": [
     "LOPINAVIR AND RITONAVIR"
    ],
    "manufacturer_name": [
     "AbbVie Inc."
    ],
    "product_ndc": [
     "0074-4014",
     "0074-3956",
     "0074-3008"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "LOPINAVIR",
     "RITONAVIR"
    ],
    "rxcui": [
     "311369",
     "597730",
     "746645",
     "847741",
     "847745",
     "847749"
    ],
    "spl_id": [
     "36abdfba-ddc2-43ae-9173-903d66a23b23"
    ],
    "spl_set_id": [
     "8290add3-4449-4e58-6c97-8fe1eec972e3"
    ],
    "package_ndc": [
     "0074-3956-46",
     "0074-4014-12",
     "0074-3008-60"
    ],
    "nui": [
     "N0000000246",
     "N0000175889",
     "N0000185503",
     "N0000190114",
     "N0000190107",
     "N0000191001",
     "N0000182137",
     "N0000185607",
     "N0000190118",
     "N0000190113",
     "N0000182141",
     "N0000191266",
     "N0000185507",
     "N0000187064",
     "N0000190117"
    ],
    "pharm_class_moa": [
     "HIV Protease Inhibitors [MoA]",
     "P-Glycoprotein Inhibitors [MoA]",
     "Cytochrome P450 3A Inhibitors [MoA]",
     "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]",
     "Cytochrome P450 2D6 Inhibitors [MoA]",
     "Cytochrome P450 2C19 Inducers [MoA]",
     "Cytochrome P450 3A Inducers [MoA]",
     "Breast Cancer Resistance Protein Inhibitors [MoA]",
     "Cytochrome P450 3A4 Inhibitors [MoA]",
     "Cytochrome P450 1A2 Inducers [MoA]",
     "Cytochrome P450 2C9 Inducers [MoA]",
     "Cytochrome P450 2B6 Inducers [MoA]",
     "UDP Glucuronosyltransferases Inducers [MoA]"
    ],
    "pharm_class_epc": [
     "Protease Inhibitor [EPC]",
     "Cytochrome P450 3A Inhibitor [EPC]"
    ],
    "unii": [
     "2494G1JF75",
     "O3J8G9O825"
    ]
   },
   "update_date": "07/24/2026",
   "therapeutic_category": [
    "Antiviral"
   ],
   "dosage_form": "Tablet",
   "presentation": "Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12)",
   "company_name": "AbbVie Inc.",
   "status": "To Be Discontinued"
  }
 ]
}